EUVIMEDEUVIMED entdecken
Leserbrief

Safety of apixaban and rivaroxaban in patients with atrial fibrillation on hemodialysis

Hiroshi Ito

European Journal of Internal Medicine · 2024

DOI: 10.1016/j.ejim.2024.02.005 ↗

Kurz gefasst

Leserbrief in der Zeitschrift European Journal of Internal Medicine, 2024. Verfasst von Hiroshi Ito. Beteiligte Einrichtung: Division of General Internal Medicine, Department of Internal Medicine, Tokyo Medical University Ibaraki Medical Center, 3-20-1 Chuo, Ami-machi, Inas…. Hauptthemen laut MEDLINE: Rivaroxaban, Atrial Fibrillation, Pyridones, Pyrazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 3 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RivaroxabanAtrial FibrillationPyridonesPyrazolesRenal DialysisFactor Xa InhibitorsHumansAgedMaleFemaleMiddle AgedStrokeKidney Failure, ChronicAged, 80 and over

Substanzen

RivaroxabanapixabanPyridonesPyrazolesFactor Xa Inhibitors

Autor:innen und Institutionen

  • Division of General Internal Medicine, Department of Internal Medicine, Tokyo Medical University Ibaraki Medical Center, 3-20-1 Chuo, Ami-machi, Inashiki-gun, Ibaraki, Japan 300-0395. Electronic address: itohirokan@yaho…

Zitieren

APA

Ito, H. (2024). Safety of apixaban and rivaroxaban in patients with atrial fibrillation on hemodialysis. European Journal of Internal Medicine. https://doi.org/10.1016/j.ejim.2024.02.005

Vancouver

Ito H. Safety of apixaban and rivaroxaban in patients with atrial fibrillation on hemodialysis. European Journal of Internal Medicine. 2024. doi:10.1016/j.ejim.2024.02.005

BibTeX
@article{Ito2024,
  author = {Ito, Hiroshi},
  title = {Safety of apixaban and rivaroxaban in patients with atrial fibrillation on hemodialysis},
  journal = {European Journal of Internal Medicine},
  year = {2024},
  doi = {10.1016/j.ejim.2024.02.005}
}
Kostenlos starten →